Skip to main content
Log in

Preclinical antitumor activity of CI-994

  • Preclinical Studies
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

CI-994 [aka: acetyldinaline; PD 123654; 4-acetylamino-N-(2′aminophenyl)-benzamide] (Figure 1) is a novel antitumor agent with a unique mechanism of action. It is the acetylated metabolite of dinaline, a compound previously identified as having cytotoxic and cytostatic activity against several murine and human xenograft tumor models. CI-994 had activity against 8/8 solid tumors tested (log cell kills at the highest non-toxic dose): pancreatic ductal adenocarcinoma #02 (4.7); pancreatic adenocarcinoma#03 (3.0; 1/6 cures); colon adenocarcinoma #38 (1.6); colon adenocarcinoma #51/A (1.1); mammary adenocarcinoma #25 (1.7); mammary adenocarcinoma #17/ADR (0.5); Dunning osteogenic sarcoma (4.0); and the human prostate carcinoma LNCaP (1.2). CI-994 had the same spectrum of activity in vivo as dinaline. It also behaved similarly in schedule comparison/toxicity trials. Prolonged administration with lower drug doses was more effective than short-term therapy at higher individual doses. If doses were kept between 40 and 60 mg/kg/injection, prolonged administration (> 50 days) was tolerated with no gross toxicity. Doses ≥90 mg/kg/injection caused lethality after 4–5 days of administration. The maximum tolerated total dose was also increased with smaller individual doses administered for prolonged intervals. Clinical Phase I trials are ongoing with this agent.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Berger MR, Richter H, Seelig MH, Eibl H, Schmahl D: New cytostatics: more activity and less toxicity. Cancer Treat Rev 17:143–154, 1990

    Google Scholar 

  2. Berger MR, Bischoff H, Fritschi E, Henne T, Herrmann M, Pool BL, Satzinger G, Schmahl D, Weiershausen U: Synthesis, toxicity and therapeutic efficacy of 4-amino-N-(2′-aminophenyl) benzamide: a new compound preferentially active in slowly growing tumors. Cancer Treat Rep 69:1415–1424, 1985

    Google Scholar 

  3. Lelieveld P, Middeldorp RJF, Van Putten LM: Effectiveness of P-aminobenzoyl-O-phenylenediamine (GOE 1734) against mouse, rat and human tumor cells. Cancer Chemother Pharmacol 15:88–90, 1985

    Google Scholar 

  4. Berger MR, Schmahl D: Antineoplastic activity of two 4-amino-N-(2′-aminophenyl)benzamide (GOE 1734) derivatives in rat mammary carcinoma. Proc Am Assoc Cancer Res 28:301, 1987

    Google Scholar 

  5. Berger MR, Richter H, Seelig MH, Eibl H, Schmahl D: New cytostatics: more activity and less toxicity. Cancer Treat Rev 17:143–154, 1990

    Google Scholar 

  6. Kraker AJ, Moore CW: Activity and effects of 4-amino-N-(2-aminophenyl)benzamide (GOE 1734, PD 104208): a compound with a novel mechanism of action, against HCT-8. Proc Am Assoc Cancer Res 30:584, 1991

    Google Scholar 

  7. Leopold WR, Hook KE, Fry DW: Activity of biochemical properties of GOE 1734 (PD 104208), an anticancer agent with a novel mechanism of activity. Proc Am Assoc Cancer Res 28:302, 1988

    Google Scholar 

  8. Hagenbeek A, Weiershausen U, Martens ACM: Dinaline: a new oral drug against leukemia? Preclinical studies in a relevant rat model for human acute myelocytic leukemia (BNML). Leukemia (Baltimore) 2:226–230, 1988

    Google Scholar 

  9. Howard C, Roberts B, Vincent P, Elliott W: N-acetyl-dinaline: a small molecule with in vivo cytostatic activity. Proc Am Assoc Cancer Res 33:393, 1992

    Google Scholar 

  10. Rummel SA, Kraker AJ, Steinkampf RW, Hook KE, Klohs WD: Role of a small molecular weight phosphoprotein in the mechanism of action of CI-994 (N-acetyldinaline). Int J Cancer 62:636–642, 1995

    Google Scholar 

  11. Rummel S, Steinkampf R, Auerbach R, Kraker A, Klohs W: Specific loss of a 16 kD phosphoprotein in colon tumor cells treated with the novel antitumor compound CI-994 [4-(acetylamino)-N-(2-aminophenyl)benzamide, N-acetyldinine]. Proc Am Assoc Cancer Res 34:369, 1993

    Google Scholar 

  12. Klohs W, Kraker A, Steinkampf R, Moore C, Dominick M: Mitochondrial involvement in the mechanism of action of the novel antitumor compound 4-(acetylamino)-N(2-aminophenyl)benzamide (PD-123654, GOE 5549). Proc Am Assoc Cancer Res 32:396, 1991

    Google Scholar 

  13. Kraker AJ, Wolven A, Fry DW, Klohs WD: Cell cycle and nucleotide metabolism effects of 4-(acetylamino)-N-(2-aminophenyl) benzamide (PD 123654, GOE 5549) in HCT-8 cells. Proc Am Assoc Cancer Res 32:396, 1991

    Google Scholar 

  14. Rummel SA, Steinkampf RW, Kraker AJ, Klohs WD: The role of protein phosphorylation in the mechanism of 4-(acetylamino)-N-(2-aminophenyl) benzamide (N-Acetyldinaline, CI-994). Proc Am Assoc Cancer Res 33:514, 1992

    Google Scholar 

  15. Corbett TH, Roberts BJ, Leopold WR, Peckham JC, Wilkoff LJ, Griswold DP Jr, Schabel FM Jr: Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of pancreas in C57B1/6 mice. Cancer Res 44:717–726, 1984

    Google Scholar 

  16. Corbett TH, Griswold DP Jr, Roberts BJ, Peckham JC, Schabel FM Jr: Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. Cancer Res 35:2434–2439, 1975

    Google Scholar 

  17. Corbett TH, Leopold WR, Dykes DJ, Roberts BJ, Griswold DP Jr, Schabel FM Jr: Toxicity and anticancer activity of a new triazine antifolate (NSC 127755). Cancer Res 42:1701–1715, 1982

    Google Scholar 

  18. Corbett TH, Griswold DP Jr, Roberts BJ, Peckham JC, Schabel FM Jr: Evaluation of single agents and combinations of chemotherapeutic agents in mouse colon carcinomas. Cancer 40:2660–2680, 1977

    Google Scholar 

  19. Corbett TH, Roberts B J, Trader MW Jr, Laster WR Jr, Griswold DP Jr, Schabel FM Jr: Response of transplantable tumors of mice to anthracenedione derivatives alone and in combination with clinically useful agents. Cancer Treat Rep 66(5): 1187–1200, 1982

    Google Scholar 

  20. Hiramoto RN, Ghanta VK: Surgical adjuvant chemotherapy of metastatic murine osteosarcoma. Int J Cancer 25:393–397, 1980

    Google Scholar 

  21. Corbett TH, Valeriote FA, Polin L et al.: Discovery of solid tumor active agents using a soft-agar-colony-formationdisk-diffusion-assay. In: Valeriote FA, Corbett TH, Baker LH (eds), Cytotoxic Anticancer Drugs: Models and Concepts for Drug Discovery and Development, pp 35–87. Norwell, Massachusetts: Kluwer Academic Publishers, 1992

    Google Scholar 

  22. LoRusso PM, Polin L, Biernat LA, Valeriote FA, Corbett TH: Activity of datelliptium acetate (NSC 311152; SR 95156A) against solid tumors of mice. Invest New Drugs 8:253–261, 1990

    Google Scholar 

  23. Corbett TH, Valeriote FA: Rodent models in experimental chemotherapy. In: Kallman RF (ed), The Use of Rodent Tumors in Experimental Cancer Therapy: Conclusions and Recommendations, pp 233–247. Elmsford, NY: Pergamon Press, 1987

    Google Scholar 

  24. Graziano M, Walsh K: Two-week oral toxicity study of CI-994 in rats. Proc Am Assoc Cancer Res 35:460, 1994

    Google Scholar 

  25. Freireich EJ, Gehan EA, Rall DP, Schmidt LH, Skipper HE: Quantitative comparison of toxicity of anticancer agents in mouse, rat, dog, monkey and man. Cancer Chemother Rep 50(4):219–244

  26. LoRusso P, Wozniak A, Foster B, Parchment R, Volpe D, Meyer M, Radulovic L, Corbett TH, Valdivieso M: Phase I trial of extended daily dosing of acetyldinaline (CI-994) (abstract). Submitted NCI-EORTC, November 1995

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

LoRusso, P.M., Demchik, L., Foster, B. et al. Preclinical antitumor activity of CI-994. Invest New Drugs 14, 349–356 (1996). https://doi.org/10.1007/BF00180810

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00180810

Key words

Navigation